Eric Costanzo, MD

Pulmonary critical care and neuro critical care physician and program director, Pulmonary and Critical Care fellowship at Jersey Shore University Medical Center with Hackensack Meridian health system and Shore Pulmonary Associates

Articles by Eric Costanzo, MD

The Biologic Era in COPD: What Mepolizumab Approval Means for Exacerbation Control

Monoclonal Antibodies and the Future of Lung Preservation in COPD

ByJoseph Khabbaza, MD ,Nikita S. Desai, MD,Eric Costanzo, MD

July 30th 2025

In this video, the last in a 6-part series, panelists discuss the potential future impact of biologics in the COPD field.

Identifying COPD Candidates for Biologics: What Clinicians Should Know

ByJoseph Khabbaza, MD ,Nikita S. Desai, MD,Eric Costanzo, MD

July 30th 2025

In this video, the fifth in a 6-part series, panelists discuss the factors that influence initiating biologics for COPD.

Next-Gen COPD Trials: What Clinicians Need from Biologic Studies

ByJoseph Khabbaza, MD ,Nikita S. Desai, MD,Eric Costanzo, MD

July 30th 2025

In this video, the fourth in a 6-part series, panelists discuss how future studies of monoclonal antibodies in COPD could be refined.

Targeting Type 2 Inflammation: COPD Lessons from Asthma Biology

ByJoseph Khabbaza, MD ,Nikita S. Desai, MD,Eric Costanzo, MD

July 30th 2025

In this video, the third in a 6-part series, panelists discuss how learnings from asthma management are informing COPD management.

From Rescue to Routine: Early Use of Biologics in COPD

ByJoseph Khabbaza, MD ,Nikita S. Desai, MD,Eric Costanzo, MD

July 30th 2025

In this video, the second in a 6-part series, panelists discuss using monoclonal antibodies in early-line COPD treatment.

The Biologic Era in COPD: What Mepolizumab Approval Means for Exacerbation Control

ByJoseph Khabbaza, MD ,Nikita S. Desai, MD,Eric Costanzo, MD

July 30th 2025

In this video, the first in a 6-part series, panelists discuss the impact of monoclonal antibodies for COPD management.

Eric Costanzo, MD

Articles by Eric Costanzo, MD

Monoclonal Antibodies and the Future of Lung Preservation in COPD

Identifying COPD Candidates for Biologics: What Clinicians Should Know

Next-Gen COPD Trials: What Clinicians Need from Biologic Studies

Targeting Type 2 Inflammation: COPD Lessons from Asthma Biology

From Rescue to Routine: Early Use of Biologics in COPD

The Biologic Era in COPD: What Mepolizumab Approval Means for Exacerbation Control

Latest Updated Articles

Trending on HCPLive

Q2 2026 Recap: Dermatology News & Updates

COMP360 Psilocybin Sustains Depression Benefit Through 26 Weeks

Hypercortisolism Recognition and Action in Resistant Hypertension

Updated Guidelines and the Current CSU Treatment Landscape

Mechanisms of Action Behind Advanced CSU Therapies